Dr. Patel Discusses Checkpoint Blockade in NSCLC

Jyoti Patel, MD
Published: Wednesday, Oct 04, 2017



Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer (NSCLC).

There have been significant responses to checkpoint blockades, but only about 20% of patients demonstrate response.

The goal now is to bring the right immunotherapy agents to a broader population, says Patel, giving more patients a chance at response.
 


Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer (NSCLC).

There have been significant responses to checkpoint blockades, but only about 20% of patients demonstrate response.

The goal now is to bring the right immunotherapy agents to a broader population, says Patel, giving more patients a chance at response.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x